Technology

Precise gene expression profiling in your qualified local laboratory

Setting the standard for reliable, reproducible results

 

 

Prosigna is powered by nCounter digital technology1

  • Strong analytical performance: sensitive, precise, and quantitative
  • Single-tube multiplexing: all 50 Prosigna genes are measured in a single reaction—no amplification required
  • Easy to use: fully automated, intuitive user interface

 

Nature_Biotech_cover.jpg

 

Nature Biotechnology features the nCounter technology

 

VIEW THE ARTICLE

 

Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.

 

References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.

The only breast cancer genomic assay FDA cleared for FFPE tissue

Convenience without compromise

gene_expression_assay_process.jpg

 

Reference: Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013.

Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II or IIIA) early-stage breast cancer to be treated with adjuvant endocrine therapy.

 

© 2014-2017 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.